SCHEMBL6884374

SCHEMBL6884374

COc1ccc(C=CC(=O)O[C@@H]2CC[C@]3(CO3)[C@@H](C3=CCCCC3)[C@@H]2OC)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 6/20 0.47
HTT P42858 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TRPM8 Q7Z2W7 2/20 0.39
RAB9A P51151 1/20 0.38
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
ABCB1 P08183 2/20 0.35
ABCB11 O95342 1/20 0.35
MAPT P10636 1/20 0.35
F3 P13726 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6886738 1.00 METAP2 (0.47) METAP2HTTMEN1KMT2ATRPM8
SCHEMBL6882901 0.81 METAP2 (0.53) METAP2HTTMEN1KMT2ATRPM8
SCHEMBL6882899 0.81 METAP2 (0.53) METAP2HTTMEN1KMT2ATRPM8
SCHEMBL6884377 0.79 HTT (0.32) METAP2HTTMEN1KMT2ATRPM8
SCHEMBL6884561 0.79 METAP2 (0.35) METAP2ALDH1A1
SCHEMBL6886678 0.74 METAP2 (0.49) METAP2HTTMEN1KMT2ATRPM8
SCHEMBL6886683 0.74 METAP2 (0.49) METAP2HTTMEN1KMT2ATRPM8
SCHEMBL23710407 0.72 METAP2 (0.81) METAP2MEN1KMT2AALDH1A1LMNA
SCHEMBL6883789 0.72 METAP2 (0.81) METAP2MEN1KMT2AALDH1A1LMNA
SCHEMBL19254377 0.72 METAP2 (0.57) METAP2HTTMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6803382-B2 1-OXASPIRO(2,5)OCTAN-6-OL DERIVATIVES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-10-12 US disclosed
US-20030134896-A1 Novel angiogenesis inhibitors and pharmaceutical and cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134896-A1 Novel angiogenesis inhibitors and pharmaceutical and cosmetic use thereof VEGFA, KDR, FLT1 METAP2 2357/4885HTT 4626/4885MEN1 3760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.